New study claims these sports are better exercise than running or swimming
For years, doctors have cited swimming and running as two of the best ways to strengthen your muscles and improve cardiovascular health. But now, new research says that racket-based sports like tennis could be even better for your body.
The new study, published in Mayo Clinic Proceedings, claims that some sports that are often considered leisurely are good for the heart and can lead to increased life expectancy. The study, which included more than 8,500 participants in Denmark, found that tennis and badminton especially were associated with the greatest longevity boost of any physical activity.
Today's Top Deals
XGIMI Prime Day deals feature the new MoGo 4 and up to 42% off smart projectors
Best deals: Tech, laptops, TVs, and more sales
Best Ring Video Doorbell deals
Furthermore, the research shows that tennis added up to 9.7 years of life expectancy, while badminton added 6.2 years on average. Comparatively, running and swimming only added 3.2 years and 3.4 years, respectively. Another recent study by British researchers also supports these findings, comparing the overall impact of various sports with the effect they have on the player's health.
A big part of why racket sports are so good for you is because they keep you in constant motion, with moments of fast sprinting and constant directional changes, all of which can benefit your body greatly. As a result, players are constantly burning calories, making tennis one of the best ways to keep your weight in check, too.
Further, the researchers agreed that the repetitive, weight-bearing motions that play a big part in racket sports can help stimulate bone growth and density, which are especially important as our bodies age. This discovery opens the door for other cardiovascular-focused sports to become viable options for those trying to lose weight instead of simply swimming or running.
Considering how difficult it can be to build a habit of exercise, and some of the other research surrounding exercise — like how time seems to slow down when you're exercising — having more than a few ways to reliably workout and burn calories will go a long way for many people.
More Top Deals
Memorial Day security camera deals: Reolink's unbeatable sale has prices from $29.98
See the
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Gizmodo
18 minutes ago
- Gizmodo
Ozempic Maker Novo Nordisk Freezes Hiring Amid Ongoing Struggles
No one stays on top forever. It's a lesson that Ozempic maker Novo Nordisk may be painfully learning about. The Danish pharmaceutical company has enacted a hiring freeze—the latest sign of a sinking financial outlook for the once-titan of the obesity treatment world. Reuters reported on the hiring freeze Wednesday. The company has faced numerous setbacks in recent months, including billions shaved off its stock market value and continued competition from cheaper, compounded versions of its blockbuster drug semaglutide. Though the freeze will apparently only apply to certain segments of the company, layoffs are likely not far off in the distance. 'We currently have a hiring freeze in non-business critical areas,' said Novo Nordisk in a statement to Reuters. Semaglutide is the active ingredient in Novo Nordisk's diabetes drug Ozempic and obesity medication Wegovy. It and similar compounds mimic the hormone GLP-1, which helps regulate insulin production and our appetite (among other functions). Though GLP-1 drugs have existed for two decades, semaglutide has proven more effective at helping people lose weight than diet and exercise alone, as well as other older medications. The approval of Wegovy in 2021 greatly reshaped the field of obesity medicine and earned plenty of money for Novo Nordisk. In 2024, the company reported about $42 billion dollars of revenue, driven by increasing sales of Wegovy and Ozempic (sometimes prescribed off-label for weight loss treatment). The company's success was so tremendous that it even helped bolster Denmark's local economy. But the company's meteoric rise has stumbled as of late for several reasons. For starters, it's no longer the only game in town, following the approval of Eli Lilly's tirzepatide for obesity (under the name Zepbound) in 2023. The drug, which combines GLP-1 with another weight-related hormone, is generally more effective than semaglutide, and people have steadily started to prefer it. Though Ozempic and Wegovy might still be more well known to the public, prescriptions of Zepbound in the U.S. now appear to be surpassing the former. Ozempic-Maker CEO Ousted Over Pharma Company's Rocky Market Downturn Novo Nordisk has also explicitly cited the emergence of the compounded drug market for GLP-1 therapy for its recent struggles. Compounded drugs are custom-made formulations of semaglutide and tirzepatide, often much cheaper, and produced by specialized pharmacies. The Food and Drug Administration has attempted to crack down on this industry, but many companies are still producing these drugs, and many people are still buying them. The fight over these compounded drugs has become so fierce that Novo Nordisk abruptly ended its newly formed partnership with telehealth company Hims in June. The company alleged that Hims was trying to deceptively market their compounded version of semaglutide over Wegovy to its users (Hims, for its part, has denied the accusation). These headwinds led Novo Nordisk to admit earlier this year that its projected sales growth in 2025 will fall short of past projections, which has since fueled further financial calamity. In May, the company fired its longtime CEO amid declining stocks. In July, investors wiped off $70 billion from the company's market value after it once again lowered its sales growth forecast for the remainder of the year. Sales of Wegovy and Ozempic do remain strong overall. And Novo Nordisk is developing other treatments intended to reclaim its throne in the obesity medicine field (including weight loss pills and drugs potentially more effective than any other treatment to date). But the company's fortunes are likely to worsen before they get better. Novo Nordisk Abruptly Ends Partnership with Hims, Claiming 'Sham Compounding' GLP-1 Drugs Departing CEO Lars Fruergaard Jørgensen stated in early August that the company, which currently employs nearly 80,000 people, will probably experience layoffs. The company's new CEO, Maziar Mike Doustdar, is also considering layoffs, according to a recent report from Danish TV2. This new era of obesity treatment isn't going anywhere anytime soon. But whether Novo Nordisk will remain the big dog on top is much more in question today than it would have been even just a few months ago.


New York Times
an hour ago
- New York Times
4 Surprising Ways Healthy Heart Habits Benefit Your Whole Body
Doctors have long endorsed a handful of practices that protect against heart disease, the leading killer of adults in America. A new review shows that following this heart-healthy guidance also benefits the body in other surprising ways, including lowering the risk of cancer and dementia, improving mobility and even increasing the chances of a healthy pregnancy. Researchers examined a decade of studies on 'Life's Simple 7,' a set of guidelines established in 2010 by the American Heart Association that reduce one's chances of developing and dying of heart disease. The guidelines include eating a heart-healthy diet, exercising, abstaining from smoking, and maintaining body weight, blood glucose, cholesterol and blood pressure within healthy limits. (Getting good sleep was added in 2022, when the list became 'Life's Essential 8.') The new review underscored how the measures collectively staved off cardiovascular disease, and also found that their positive health effects extended beyond the heart, said Liliana Aguayo, a research assistant professor of nursing at Emory University and the lead author of the paper. Following the guidance may prevent a number of chronic diseases, as well as help maintain mobility, vision, hearing and other functions. The benefits begin at the cellular level by reducing inflammation and most likely affecting other processes of aging, too, said Anthony Molina, a professor of medicine at the University of California, San Diego, who specializes in the science of aging. Heart disease and many other chronic diseases are primarily diseases of aging, but you can start accumulating risk with poor cardiovascular health earlier in life. 'From the top of your head to the tip of your toenail, pretty much everything is going to be better if you optimize your cardiovascular health,' said Dr. Donald Lloyd-Jones, a professor of cardiology at Boston University who led the development of the original framework and worked on the new review. Want all of The Times? Subscribe.


Medscape
an hour ago
- Medscape
New First-Line Option for Advanced Bladder Cancer
The National Institute for Health and Care Excellence (NICE) has recommended the combination of enfortumab vedotin (Padcev, Astellas) with pembrolizumab (Keytruda, MSD) as a first-line option for adults with unresectable or metastatic urothelial cancer who are eligible for platinum-based chemotherapy. More than 1200 people in England are expected to benefit each year. Clinical experts described the combination therapy as a "step change" in bladder cancer management. Until now, treatment options for this patient group have seen little meaningful progress since the 1980s. Enfortumab vedotin is an antibody-drug conjugate consisting of an antibody targeting Nectin-4, a protein highly expressed in urothelial carcinoma cells. After binding, it causes the cells to release monomethyl auristatin E, resulting in cell death. Pembrolizumab, its combination partner, is a PD-1 inhibitor. High Disease Burden Urothelial cancer accounts for around 90% of bladder cancers, affecting more than 18,000 people annually in England. Prognosis is poor, with only 10% of patients with stage 4 disease surviving for 5 years or more. Current standard treatments include platinum-based chemotherapy ( cisplatin or carboplatin with gemcitabine), followed by avelumab maintenance therapy if the cancer has not progressed. However, only about 12% of patients see improvement with chemotherapy, underscoring the need for better options. Patient experts described living with metastatic urothelial cancer as "intensely challenging and emotionally exhausting', affecting work, travel, and physical activity. Action Bladder Cancer UK called the announcement a 'very welcome, and significant, step forward for this hard-to-treat cancer'. Clinical Evidence The recommendation in final draft guidance was supported by results from the phase 3 EV-302 trial, which enrolled 886 adults with untreated, unresectable, locally advanced, or metastatic urothelial cancer. Participants were randomly assigned in a 1:1 ratio to receive either enfortumab vedotin–pembrolizumab or standard chemotherapy. Enfortumab vedotin–pembrolizumab nearly doubled the median time to disease progression or death to 12.5 months, compared with 6.3 months for chemotherapy. Median overall survival was also improved, at 33.8 months versus 15.9 months with chemotherapy. Helen Knight, director of medicines evaluation at NICE, said the drug combination is 'highly promising and effective,' adding that these clinical trial results highlight the 'tremendous difference' it could make to the length and quality of people's lives. Cost and NHS Access Enfortumab vedotin is listed at £578 per 20 mg vial or £867 per 30 mg vial. Pembrolizumab costs £2630 per 100 mg vial, excluding VAT. The drugs will be supplied through confidential commercial arrangements with the NHS. NICE's appraisal committee applied a severity modifier, reflecting the high disease burden, and concluded that the therapy met acceptable cost-effectiveness thresholds. The treatment will be available immediately across the NHS in England, with funding required within 90 days of final publication of the guidance.